Inozyme Pharma, Inc.

The momentum for this stock is not very good. Inozyme Pharma, Inc. is not very popular among insiders. Tradey thinks it is not wise to invest in Inozyme Pharma, Inc..

News

Why Analyst Says Rare Disease-Focused Inozyme Pharma Stock 'Could Be Worth A Look'

Benzinga Stifel initiates coverage on Inozyme Pharma with a Buy rating and a $16 price target, highlighting INZ-701's potential to treat rare diseases like ENPP1 and ABCC6 deficiencies.\n more…

Inozyme Pharma, Inc. (NASDAQ:INZY) Given Average Rating of "Buy" by Brokerages

Ticker Report Inozyme Pharma, Inc. (NASDAQ:INZY - Get Free Report) has been assigned a consensus recommendation of "Buy" from the six analysts that are covering the company, MarketBeat.com reports. Six research...\n more…

Inozyme Pharma to Participate at the 2024 Wells Fargo Healthcare Conference

Globe Newswire BOSTON, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) ( the Company or Inozyme ), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare...\n more…

California State Teachers Retirement System Decreases Holdings in Inozyme Pharma, Inc. (NASDAQ:INZY)

Zolmax California State Teachers Retirement System lowered its stake in shares of Inozyme Pharma, Inc. (NASDAQ:INZY - Free Report) by 38.9% in the 1st quarter, Holdings Channel.com reports. The...\n more…

Inozyme Pharma, Inc. (NASDAQ:INZY) Receives $16.17 Consensus Price Target from Brokerages

Zolmax Inozyme Pharma, Inc. (NASDAQ:INZY - Get Free Report) has earned a consensus recommendation of "Buy" from the six research firms that are currently covering the stock, Marketbeat Ratings reports. Six...\n more…

Inozyme Pharma (NASDAQ:INZY) Given Buy Rating at Jefferies Financial Group

Zolmax Inozyme Pharma (NASDAQ:INZY - Get Free Report)s stock had its "buy" rating reiterated by analysts at Jefferies Financial Group in a research report issued to clients and investors on Tuesday...\n more…